Muscle electrical stimulation body contouring unit OptiLIFT™

trolley-mounted

Product overview
OptiLIFT™ is a non‑surgical periorbital muscle stimulator designed to improve lower eyelid laxity and blink function by toning and conditioning the periorbital musculature. The system integrates Dynamic Muscle Stimulation (DMSt) with optional Radio Frequency (RF) and an upgradeable VoluDerm microneedling applicator to combine muscle conditioning and skin resurfacing for comprehensive functional and aesthetic outcomes. The periorbital applicator includes three predefined presets adapted to delicate facial contours.

Technology

• Dynamic Muscle Stimulation (DMSt): electrical pulses that activate neural pathways to elicit controlled contractions of periorbital muscles for strengthening and improved blink mechanics.
• Radio Frequency (RF): controlled thermal energy delivery to dermal layers to stimulate collagen synthesis and tissue tightening.
• VoluDerm / Microneedling (optional): microneedling with RF thermal energy to promote resurfacing, wound-healing response and skin regeneration.

Intended use & indications
OptiLIFT™ components are intended for conditioning and strengthening periorbital muscles (OptiLIFT applicator). When equipped with the VoluDerm applicator, the system is indicated for dermatological resurfacing and ablation procedures. The device is intended for use by licensed healthcare professionals in a clinical setting and is not intended to treat systemic medical diseases.

Benefits & clinical outcomes
Clinical data indicate functional and symptomatic improvements after a short treatment course (reported outcomes commonly observed after four sessions in the cited dataset). Reported clinical metrics include:

• +286% increase in tear breakup time (TBUT)
• +70% improvement in blink rate and quality
• ≥75% reduction in lower lid laxity
• Improvement in meibomian gland function and signs of dry eye disease (DED)

Device design & usability

• Ergonomic industrial design with adjustable features to accommodate clinical workflows and patient comfort.
• Periorbital-specific applicators/handpieces with three presets matched to facial anatomy.
• Upgradeable microneedling handpiece for resurfacing and regeneration protocols.

Clinical validation
OptiLIFT™ has been evaluated in clinical studies applying DMSt below the eyelids to improve blinking in dry eye patients (reference: Chelnis JG, Chelnis A. Clin Ophthalmol. 2025). Key reported metrics include TBUT, blink parameters, lower lid laxity reduction and meibomian gland improvements.

Warnings & contraindications

• Contraindicated in patients with pacemakers, defibrillators, implanted electronic devices, or metal implants in the treatment area.
• Possible adverse effects during or after treatment: significant pain, skin texture damage (blister, burn), pronounced erythema, excessive edema, bruising, pruritus, pigmentation changes, scarring, transient acneiform eruptions.
• Consult the official user manual and safety documentation for the full list of contraindications and precautions.

Clinical workflow notes

• Typical treatment protocol: short series of sessions (example outcomes reported after four sessions).
• Applicator presets and ergonomics are designed to facilitate safe periorbital application under professional supervision.

Technical specifications

• Commercial name: OptiLIFT™
• Integrated technologies: DMSt, RF, optional VoluDerm microneedling with RF thermal energy
• Applicator: periorbital-specific handpiece with three predefined presets
• Intended operators: licensed healthcare practitioners
• Indications: muscle conditioning (OptiLIFT applicator); dermatological ablation/resurfacing with VoluDerm
• Reported clinical outcomes: TBUT +286%, blink improvement +70%, lower lid laxity decrease ≥75%
• Contraindications: implanted electronic devices, metal implants in treatment area
• Optional upgrades: VoluDerm microneedling for resurfacing and regeneration
• Reference: Chelnis JG, Chelnis A. Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients. Clin Ophthalmol. 2025;19:1057-1071